{"nctId":"NCT00506493","briefTitle":"Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent","startDateStruct":{"date":"2007-09"},"conditions":["Atrial Fibrillation"],"count":75,"armGroups":[],"interventions":[{"name":"Cardioblate Surgical Ablation System","otherNames":[]},{"name":"Surgical RF Ablation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients must have a documented history of persistent AF as defined by the ACC/AHA/ESC Guidelines: Characterized as episodes of non-self-terminating atrial fibrillation that usually lasts more than 7 days.\n2. Concomitant indication (other than AF) for open-heart surgery for one or more of the following:\n\n   * Mitral valve repair or replacement\n   * Aortic valve repair or replacement\n   * Tricuspid valve repair or replacement\n   * Atrial septal defect (ASD) repair\n   * Patent foramen ovale (PFO) closure\n   * Coronary artery bypass procedures\n3. Greater than or equal to 18 years of age\n4. Able and willing to comply with study requirements by signing a consent form\n5. Must be able to take the anticoagulant warfarin (Coumadin)\n\nExclusion Criteria:\n\n1. Wolff-Parkinson-White syndrome\n2. NYHA Class = IV\n3. Left ventricular ejection fraction â‰¤ 30%\n4. Need for emergent cardiac surgery (i.e. cardiogenic shock)\n5. Previous atrial ablation for AF, AV-nodal ablation, or surgical Maze procedure\n6. Contraindication for anticoagulation therapy\n7. Left atrial diameter \\> 7.0 cm\n8. Preoperative need for an intra-aortic balloon pump or intravenous inotropes\n9. Renal failure requiring dialysis or hepatic failure\n10. Life expectancy of less than one year\n11. Pregnancy or desire to be pregnant within 12 months of the study treatment.\n12. Current diagnosis of active systemic infection\n13. Documented MI 6 weeks prior to study enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy Endpoint: The Percent of Patients Off Class I or III Antiarrhythmic Drugs and Out of AF as Determined by 24 Hour Holter Recording at 9 Months","description":"Subject's cardiac rhythm was assessed by wearing a Holter Monitor for 24 hours","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Safety Endpoint: Composite Acute Major Adverse Event Rate, Within 30 Days Post-procedure or Hospital Discharge","description":"Major Adverse Events were defined to include: mediastinitis, death, myocardial infarction, stroke, transient ischemic attacks (TIA), pulmonary embolism, peripheral arterial embolism, and esophageal injury.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints: The Percent of Patients Out of AF, Regardless of Antiarrhythmic Drug Status, as Determined by a 24 Hour Holter Recording at 9 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Endpoints: Composite 9-month Major Adverse Event Rate, Post-procedure","description":"Major Adverse Events were defined to include: mediastinitis, death, myocardial infarction, stroke, transient ischemic attacks (TIA), pulmonary embolism, peripheral arterial embolism, and esophageal injury.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":45,"n":75},"commonTop":["Pleural Effusion","Atelectasis","Renal Insufficiency/Failure: No Dialysis Required","Hemodynamic Instability","Anemia"]}}}